Please assess the completion status of the following clinical trial:

Trial Title: Jet Injection for Influenza

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged ≥18 and ≤64 years of age at the time of enrollment~* Willing and able to give informed consent after reading the consent form and adequate opportunity to discuss the study with the investigator or qualified designee~* Willing and able to adhere to all protocol required study procedures and to attend scheduled visits.~* Able to receive the TIV influenza vaccine, based on University of Colorado Health (UCH) employee health flu screening guidelines.~* Stable health status with no exclusionary medical or neuropsychiatric conditions as determined during the screening evaluation and based on the clinical judgment of the investigator or qualified designee.~* Access to a consistent means of telephone contact~Exclusion Criteria:~* Presence of any febrile illness (oral temperature \>38°C) on the day of immunization. Such subjects will be reevaluated for enrollment after resolution of illness.~* Presence of significant acute or chronic uncontrolled medical or neuropsychiatric illness and /or presence of any significant condition that may prohibit inclusion as determined by the investigator or his qualified designee. Uncontrolled is defined as: requiring institution of a new treatment within 1 month prior to study enrollment or change in medication dosage in the month prior to study enrollment.~* Any immunosuppressive condition including: history of HIV infection, cancer or cancer treatment within 3 years of study enrollment, systemic glucocorticoids (in a dose ≥10 mg prednisone daily or equivalent for more than 7 consecutive days or for 10 or more days in total) within 1 month of study enrollment, or any other cytotoxic or immunosuppressive drug within 3 months of study enrollment. Any significant disorder of coagulation that would increase the risk of intramuscular injections or treatment with Coumadin derivatives or heparin.~* Known or suspected to be allergic to eggs, chicken protein, gentamicin or influenza vaccine.~* History of severe or previous serious adverse reaction after an influenza vaccination.~* Receipt of any immunoglobulin and/or blood products within 3 months of immunization or planned administration of any of these products during the study period.~* Prior history of any demyelinating disease including Guillain-Barre syndrome.~* Presence of an active neurological disorder.~* History of significant alcohol or drug abuse within one year prior to study enrollment.~* Influenza vaccination or laboratory confirmed influenza infection within the previous six months before study vaccination or planned influenza vaccination during the study period.~* Planned administration of any non-influenza vaccines 30 days prior to the study or during the study period.~* Pregnant or plans to become pregnant during the study period.~* Currently enrolled in another vaccine or drug study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- STRATIS Needle-Free (Type: EXPERIMENTAL): Patients assigned to this arm will receive AFLURIA vaccine administered using the Stratis needle-free injection device.
- Needle-Syringe (Type: ACTIVE_COMPARATOR): Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete